文献速递胸部肿瘤

动态ctDNA测序解码ALK阳性NSCLC对恩沙替尼的演化反应

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
PubMed 文献 · J Thorac Oncol · 2021-02-13

本研究在多中心2期试验中,对克唑替尼进展后的ALK阳性NSCLC患者进行动态ctDNA测序,探索TP53突变对肿瘤演化及恩沙替尼耐药机制的影响。结果显示基线TP53突变与更差的无进展生存显著相关,TP53突变患者疾病进展时突变数量更多,并揭示了ALK依赖性和非依赖性耐药机制。

要点

  • 基线TP53突变与恩沙替尼治疗后更差的无进展生存显著相关。
  • TP53突变患者在疾病进展时出现更多新发突变,提示遗传演化加速。
  • 疾病进展时继发性ALK突变G1269A、G1202R和E1210K频率和丰度显著增加。

核心结论

  • 动态ctDNA分析有助于监测ALK阳性NSCLC的肿瘤演化。
  • TP53突变促进遗传演化并加速耐药发生。
  • 恩沙替尼耐药涉及ALK依赖性机制(主要为G1269A、G1202R和E1210K突变)和ALK非依赖性机制。

研究设计与样本

  • 多中心2期试验,纳入克唑替尼进展后的ALK阳性NSCLC患者接受恩沙替尼治疗。
  • 在基线、第3周期第1天和疾病进展时采集血样进行ctDNA分析,使用212基因panel。
  • 共从168例患者收集440份样本。

主要发现

  • 基线TP53突变率为20.2%,与更差的无进展生存显著相关(4.2个月 vs 11.7个月,p < 0.0001)。
  • 基线时TP53突变患者突变负荷高于无TP53突变患者(13.79 ± 3.72 vs 4.67 ± 0.39,p < 0.001)。
  • 第3周期第1天两组突变负荷无显著差异(5.89 ± 2.25 vs 3.72 ± 0.62,p = 0.425)。
  • 疾病进展时TP53突变患者出现更多突变(7.07 ± 1.25 vs 3.20 ± 0.33,p = 0.003)。
  • 疾病进展时继发性ALK突变G1269A、G1202R和E1210K的频率和丰度较基线显著增加。

临床怎么用

  • 动态ctDNA监测可用于评估ALK阳性NSCLC患者的肿瘤演化和耐药机制。
  • 基线TP53突变状态可能有助于识别恩沙替尼治疗预后较差的患者。
  • 疾病进展时ctDNA分析可揭示继发性ALK突变和ALK非依赖性耐药机制,指导后续治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: By implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored the impact of TP53 mutations on tumor evolution and resistance mechanisms to ensartinib in patients with ALK-positive NSCLC. METHODS: In a multicenter phase 2 trial, patients with ALK-positive NSCLC who progressed on crizotinib were treated with ensartinib. Blood samples for ctDNA analysis were collected at baseline, cycle 3 day 1, and progression disease (PD) and analyzed with a 212-gene panel. RESULTS: A total of 440 samples were collected from 168 patients. Baseline TP53 mutations (20.2%) significantly correlated with inferior progression-free survival (4.2 mo versus 11.7 mo, p < 0.0001). Patients with TP53 mutations had higher mutation load than those without TP53 mutations at baseline (13.79 ± 3.72 versus 4.67 ± 0.39, p < 0.001). Although there was no significant difference in mutation load between these groups at cycle 3 day 1 (5.89 ± 2.25 versus 3.72 ± 0.62, p = 0.425), patients with mutated TP53 developed more mutations at PD (7.07 ± 1.25 versus 3.20 ± 0.33, p = 0.003). Frequency and abundance of secondary ALK mutations G1269A, G1202R, and E1210K increased markedly at PD than baseline. In patients without secondary ALK mutations, we identified ALK-independent resistance mechanisms including bypass signaling activation, downstream effector protein reactivation, epithelial-mesenchymal transformation, and epigenetic dysregulation. CONCLUSIONS: Our study highlighted the advantage of ctDNA analysis for monitoring tumor evolution. TP53 mutations promoted genetic evolution and accelerated occurrence of resistance. We also unveiled ALK-dependent resistance mechanisms, mainly by G1269A, G1202R, and E1210K mutations, and ALK-independent resistance mechanisms to ensartinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yang Y, Huang J, Wang T, et al. Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. J Thorac Oncol. 2021. PMID: 33588113. doi:10.1016/j.jtho.2021.01.1615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。